Since there was no systematic review that summarized the long-term incidence of mortality and hospitalization for heart failure (HHF) in patients with T2DM and HF who used SGLT-2 inhibitor, we tried to conduct a systematic review and meta-analysis and identify the population, which would benefit more from the treatment. This evidence concerns the gene SLC5A2 and heart failure.